Nevro (NYSE:NVRO) and Boston Scientific (NYSE:BSX) announced today that they reached a settlement over intellectual property litigations. The settlement gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, with Nevro given the freedom to operate using the features and capabilities […]
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ 7 brain-computer interface companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
CVRx stock up on Street-beating Q2 sales, raised guidance
CVRx (Nasdaq:CVRX) shares were up this morning on second-quarter results that beat the consensus revenue forecast. The Minneapolis-based neuromodulation technology developer posted losses of $11.1 million, or 54¢ per share, on sales of just over $5 million for the three months ended June 30, 2022, for a more than $6 million bottom-line gain despite remaining […]
Abbott launches digital health app for neurostimulation in Canada
Abbott (NYSE:ABT) announced today that it received Health Canada licensing for its NeuroSphere Virtual Clinic, enabling it to launch the app. The Abbott Park, Illinois–based company designed the remote programming technology — the first of its kind in Canada — with compatibility with Abbott’s suite of neuromodulation technologies, offering the potential to increase access to […]
Viz.ai, Hyperfine partner on new MRI, workflow paradigm
Viz.ai announced today that it partnered with Hyperfine (Nasdaq:HYPR) to bring magnetic resonance imaging (MRI) to the patient’s bedside. San Francisco-based Viz.ai develops the Viz LVO, its flagship product designed to leverage advanced deep learning to communicate time-sensitive information about stroke patients straight to a specialist who can intervene and treat the patient. Hyperfine develops […]
Studies support Imperative Care’s stroke treatment platform
Imperative Care announced today that data supports the use of its Zoom Stroke solution for fast and effective clot removal. Campbell, California-based Imperative Care designed the Zoom solution to treat those with acute ischemic stroke. It features the Zoom 88 large distal platform for neurovascular access, four-vessel-matched Zoom aspiration catheters, the Zoom Pump, Zoom POD […]
Calyx, Qynapse partner on AI-enhanced imaging for clinical trials
Calyx announced today that it partnered with Qynapse to use AI-powered neuroimaging analysis technology for central nervous system disorders. The partnership will combine Calyx’s eClinical and regulatory solutions and services with Qynapse’s artificial intelligence (AI)-based QyScore and QyPredict platforms for customers developing medical treatments for central nervous system (CNS) disorders. “We’re delighted to add Qynapse’s […]
Neuronetics inks deal with Alleviant to supply NeuroStar to mental health clinics
Neuronetics (Nasdaq:STIM) announced today that it entered into a commercial partnership with Alleviant Health Centers. Under the agreement, Malvern, Pennsylvania-based Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to Alleviant and its clinics. According to a news release, an initial six NeuroStar advanced therapy systems — Neuronetics’ non-drug, non-invasive treatment […]
ArchiMed completes $1.2B acquisition of Natus Medical
Natus Medical (Nasdaq:NTUS) announced today that ArchiMed’s investment firm completed its previously announced acquisition of the company. In April, the company announced that the MED Platform II fund of ArchiMed — an investment firm focused on the healthcare industry — would acquire Natus, a developer of medical devices for screening, diagnosing and treating disorders affecting […]
FDA clears RapidAI platform for assessing neuro injury severity
RapidAI announced today that it received FDA clearance for its Rapid Hyperdensity, a new addition to its RapidAI platform. San Mateo, California-based RapidAI designed Rapid Hyperdensity to give physicians a tool to quickly assess the severity of injury in patients with acute neuro conditions, such as traumatic brain injury and brain hemorrhages, to allow for […]
Stimdia Medical raises $16M for neurostim to get people off ventilators
Stimdia Medical announced recently that it completed the initial closing of a $16 million tranche of its Series B financing round. Solas Bioventures led the financing round, while new strategic partners and existing investors Draper Triangle Ventures also contributed funding. Minneapolis-based Stimdia designed its pdSTIM system to offer a tool for addressing high-risk patients, including […]
FDA clears Neuronetics’ therapy for anxious depression
Neuronetics (Nasdaq:STIM) announced today that the FDA cleared a new indication for its transcranial magnetic stimulation (TMS) system. The new indication for the NeuroStar advanced therapy for mental health allows the system to treat anxiety symptoms for adult patients who suffer from major depressive disorder (MDD), also known as anxious depression. NeuroStar is a non-drug, […]